Invention Grant
US09126979B2 Compounds for inhibiting the interaction of BCL2 with binding partners
有权
用于抑制BCL2与结合伴侣相互作用的化合物
- Patent Title: Compounds for inhibiting the interaction of BCL2 with binding partners
- Patent Title (中): 用于抑制BCL2与结合伴侣相互作用的化合物
-
Application No.: US14366857Application Date: 2012-12-12
-
Publication No.: US09126979B2Publication Date: 2015-09-08
- Inventor: Daniel Ford , John Robert Porter , Michael Scott Visser , Naeem Yusuff
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Brinks Gilson & Lione
- International Application: PCT/US2012/069270 WO 20121212
- International Announcement: WO2013/096059 WO 20130627
- Main IPC: C07D401/10
- IPC: C07D401/10 ; A61K31/4725
Abstract:
The present invention relates to compounds of formula I: in which R1, R2, R3 and R4 are as defined in the Summary of the Invention. Compounds of formula I are capable of disrupting the BCL-2 interations with proteins containing a BH3 domain. Disrupting this interaction can restore the anti-apoptotic function of BCL-2 in cancer cells and tumor tissue expressing BCL-2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancerous diseases.
Public/Granted literature
- US20140343093A1 COMPOUNDS FOR INHIBITING THE INTERACTION OF BCL2 WITH BINDING PARTNERS Public/Granted day:2014-11-20
Information query
